Blood clots and Johnson & Johnson vaccine: What you need to know
April 27, 2021. Summarized by summa-bot.
Compression ratio: 20.7%. 1 min read.
Administration of the Johnson & Johnson Covid-19 vaccine can be resumed after a pause due to reports of a very rare type of blood clot, according to health officials. Here's what you need to know about possible symptoms and who is at risk.
"This adverse event is rare, occurring at a rate of about 7 per 1 million vaccinated women between 18 and 49 years old," the CDC wrote.
The six women developed symptoms of this "rare and severe type of blood clot" between six and 13 days after their J&J vaccination, the CDC said.
For five of the six women, headache was the "initial presenting feature," said Dr. Tom Shimabukuro, vaccine safety lead with the CDC's Covid-19 Response Team, during a meeting of the CDC's Advisory Committee on Immunization Practices on April 14.
Since the mid-April announcement, CDC investigators discovered another nine cases, all in women, and all in conjunction with thrombocytopenia, a condition in which people have a low blood count of platelets, the sticky, colorless blood cells that help blood clot.
"Reports of adverse events following the use of J&J/Janssen vaccine suggest an increased risk of a rare adverse event called thrombosis with thrombocytopenia syndrome (TTS)," the CDC wrote Monday in its updated guidance.
"Nearly all reports of this serious condition, which involves blood clots with low platelets, have been in adult women younger than 50 years old," the CDC said in the new posting.
However, if you received the J&J vaccine more than a month ago, the risk is "very low," said CDC principal deputy director Dr. Anne Schuchat during the mid-April briefing.